Endogenous opioids and liver disease

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 1, 2006, Pages 1-11

  Mani, Ali R ^a   Rasool, Reza ^a   Montagnese, Sara ^a   Dehpour, Ahmad R ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL MEDULLA DOCOSAPEPTIDE; BETA ENDORPHIN; DELTA OPIATE RECEPTOR; DYNORPHIN A; DYNORPHIN B; ENDOMORPHIN 1; ENDOMORPHIN 2; ENDORPHIN; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN; METENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR; OPIATE; UNCLASSIFIED DRUG;

CARDIOVASCULAR MALFORMATION; CHOLESTASIS; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; EXTRAHEPATIC BILE DUCT OBSTRUCTION; HEPATIC ENCEPHALOPATHY; HEPATOBILIARY SYSTEM; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PRURITUS; REVIEW;

ANIMALS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; MICE; MODELS, THEORETICAL; OPIOID PEPTIDES; SYNAPTIC TRANSMISSION;

EID: 29744441066     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520500287533     Document Type: Review

References (114)

1. Gutstein HB, Akil H. Opioid analgesics. In: Hardman JG, Limird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill; 2001. pp 569-619.
2. Musto DF. Opium, cocaine and marijuana in American history. Sci Am 1991;265:40-7.
3. Luderitz B. Historical development of antiarrhythmic drug therapy. In: History of the disorders of cardiac rhythm. New York: Futura Publishing Company; 1995. pp 83-106.
4. Robinson R. The structural relations of natural products. Oxford: Oxford University Press; 1955.
5. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996;48:567-92.
6. Stefano GB, Hartman A, Bilfinger TV, Magazine HI, Liu Y, Casares F, et al. Presence of the mu3 opiate receptor in endothelial cells. Coupling to nitric oxide production and vasodilation. J Biol Chem 1995;270:30290-3.
7. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975;258:577-80.
8. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA 1979;76:6666-70.
9. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997;386:499-502.
10. Weitz CJ, Faull KF, Goldstein A. Synthesis of the skeleton of the morphine molecule by mammalian liver. Nature 1987;330:674-7.
11. Stefano GB, Goumon Y, Casares F, Cadet P, Fricchione GL, Rialas C, et al. Endogenous morphine. Trends Neurosci 2000;23:436-42.
12. Standifer KM, Pasternak GW. G proteins and opioid receptor-mediated signalling. Cell Signal 1997;9:237-48.
13. Smythe CM, Gilmore JP. The effect of morphine on hepatic blood flow in the normal anesthetized dog. J Pharmacol Exp Ther 1995;114:221-4.
14. Roberts SM, Skoulis NP, James RC. A centrally-mediated effect of morphine to diminish hepatocellular glutathione. Biochem Pharmacol 1987;36:3001-5.
15. James RC, Wessinger WD, Roberts SM, Millner GC, Paule MG. Centrally mediated opioid induced depression of hepatic glutathione: effects of intracerebroventricular administration of mu, kappa, sigma and delta agonists. Toxicology 1988;51:267-79.
16. Wittert G, Hope P, Pyle D. Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun 1996;218:877-81.
17. Jaume M, Jacquet S, Cavailles P, Mace G, Stephan L, Blanpied C, et al. Opioid receptor blockade reduces Fas-induced hepatitis in mice. Hepatology 2004;40:1136-43.
18. Dobrenis K, Makman MH, Stefano GB. Occurrence of the opiate alkaloid-selective mu3 receptor in mammalian microglia, astrocytes and Kupffer cells. Brain Res 1995;24:239-48.
19. Ebrahimkhani MR, Kiani S, Kendall T, Shariftabrizi A, Tavangar SM, Payabvash S, et al. Naltrexone, an opioid antagonist, attenuates liver fibrosis in bile duct ligated rats. (submitted to Gut).
20. Bergasa NV, Sabol SL, Young WS 3rd, Kleiner DE, Jones EA. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995;268:G346-G54.
21. Bergasa NV, Liau S, Homel P, Ghali V. Hepatic Metenkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002;22:107-13.
22. Thune A, Jivegard L, Pollard H, Moreau J, Schwartz JC, Svanvik J. Location of enkephalinase and functional effects of [Leu5] enkephalin and inhibition of enkephalinase in the feline main pancreatic and bile duct sphincters. Clin Sci (London) 1992;82:169-73.
23. Bergasa NV, Zhou J, Ravi J, Shi Q. The opioid peptide analog D-Ala2-Met-enkephalinamide decreases bile flow by a central mechanism. Peptides 1999;20:979-86.
24. May B, Helmstaedt D. Liver disease in drug addicts: clinical course-toxicological and clinical pharmacological aspects. Int J Clin Pharmacol Biopharm 1975;12:50-6.
25. de Araujo MS, Gerard F, Chossegros P, Porto LC, Barlet P, Grimaud JA. Vascular hepatotoxicity related to heroin addiction Virchows Arch A Pathol Anat Histopathol 1990;417:497-503.
26. Mani AR, Babaie A, Dehpour AR. Naltrexone is protective against liver damage induced by biliary obstruction. Toxicology 2001;164:131.
27. Gaskari SA, Mani AR, Ejtemaei-Mehr S, Namiranian K, Homayoun H, Ahmadi H. Do endogenous opioids contribute to the bradycardia of rats with obstructive cholestasis? Fundam Clin Pharmacol 2002;16:273-9.
28. Ghaffari K, Savadkuhi ST, Honar H, Riazi K, Shafaroodi H, Moezi L. Obstructive cholestasis alters intestinal transit in mice: role of opioid system. Life Sci 2004;76:397-406.
29. Ebrahimkhani MR, Payabvash S, Mani AR, Shariftabrizi S, Kiani S, Pasalar P. Cholestasis and systemic oxidative stress: Roles for endogenous opioids. J Hepatol 2004; 40(Suppl 1):91.
30. Campbell SJ, Hughes PM, Iredale JP, Wilcockson DC, Waters S, Docagne F. CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury. FASEB J 2003;17:1168-70.
31. Svegliati-Baroni G, de Minitics S, Marzioni M, Saccomanno S, Benedetti A. Opioid receptors are differentially expressed during the process of hepatic stellate cell activation and modulate their proliferation and the development of liver fibrosis: An in vitro and in vivo study. Hepatology 2004;40(Suppl 1):611A.
32. Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, Pleasure DE, et al. Morphine enhances hepatitis C virus (HCV) replicon expression. AmJ Pathol 2003;163:1167-75.
33. Thornton JR, Losowsky MS. Plasma methionine enkephalin concentration and prognosis in primary biliary cirrhosis. Br Med J 1988;297:1241-2.
34. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Br Med J 1988;297:1501-4.
35. Thornton JR, Losowsky MS. Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J Hepatol 1989;8:53-9.
36. Thornton JR, Losowsky MS. Plasma leucine enkephalin is increased in liver disease. Gut 1989;30:1392-5.
37. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 1992;15:220-4.
38. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992;103:630-5.
39. Bergasa NV, Alling DW, Vergalla J, Jones EA. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994;20:85-90.
40. Ghafourifar P, Dehpour AR, Akbarloo N. Inhibition by L-NA, a nitric oxide synthase inhibitor of naloxone-precipitated withdrawal signs in a mouse model of cholestasis. Life Sci 1997;60:265-70.
41. Dehpour AR, Akbarloo N, Ghafourifar P. Endogenous nitric oxide modulates naloxone-precipitated withdrawal signs in a mouse model with acute cholestasis. Behav Pharmacol 1998;9:77-80.
42. Dehpour AR, Mani AR, Amanlou M, Nahavandi A, Amanpour S, Bahadori M. Naloxone is protective against indomethacin-induced gastric damage in cholestatic rats. J Gastroenterol 1999;34:178-81.
43. Dehpour AR, Rastegar H, Jorjani M, Roushanzamir F, Joharchi K, Ahmadiani A. Subsensitivity to opioids is receptor-specific in isolated guinea pig ileum and mouse vas deferens after obstructive cholestasis. J Pharmacol Exp Ther 2000;293:946-51.
44. Dehpour AR, Sadeghipour HR, Nowroozi A, Akbarloo N. The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum Psychopharmacol 2000;15:423-8.
45. Dehpour AR, Samini M, Rastegar H, Ardeshiri AJ, Roushanzamir F, Jorjani M, et al. Effect of NMDA receptor antagonist on naloxone-precipitated withdrawal signs in cholestatic mice. Hum Psychopharmacol 2000;15:213-8.
46. Dehpour AR, Samini M, Arad MA, Namiranian K. Clonidine attenuates naloxone-induced opioid-withdrawal syndrome in cholestatic mice. Pharmacol Toxicol 2001;89:129-32.
47. Namiranian K, Samini M, Mehr SE, Gaskari SA, Rastegar H, Homayoun H, et al. Mesenteric vascular bed responsiveness in bile duct-ligated rats: roles of opioid and nitric oxide systems. Eur J Pharmacol 2001;423:185-93.
48. Nahavandi A, Mani AR, Homayounfar H, Akbari MR, Dehpour AR. The role of the interaction between endogenous opioids and nitric oxide in the pathophysiology of ethanol-induced gastric damage in cholestatic rats. Fundam Clin Pharmacol 2001;15:181-7.
49. Rastegar H, Homayoun H, Afifi M, Rezayat M, Dehpour AR. Modulation of cholestasis-induced antinociception by CCK receptor agonists and antagonists. Eur Neuropsychopharmacol 2002;12:111-8.
50. Demehri S, Namiranian K, Mehr SE, Rastegar H, Shariftabrizi A, Gaskari SA, et al. Alpha-2-adrenoceptor hyporesponsiveness in isolated tissues of cholestatic animals: involvement of opioid and nitric oxide systems. Life Sci 2003;73:209-20.
51. Demehri S, Samini M, Namiranian K, Rastegar H, Mehr SE, Homayoun H, et al. Alpha 2-adrenoceptor and NO mediate the opioid subsensitivity in isolated tissues of cholestatic animals. Auton Autacoid Pharmacol 2003;23:201-7.
52. Schoenfield LJ, Sjovall J, Perman E. Bile acids on the skin of patients with pruritic hepatobiliary disease. Nature 1967;213:93-4.
53. Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 1974;109:678-81.
54. Ghent CN, Bloomer JR. Itch in liver disease: facts and speculations. Yale J Biol Med 1979;52:77-82.
55. Duffy BL. Itching as a side-effect of epidural morphine. Anaesthesia 1981;36:67.
56. Thomas DA, Williams GM, Iwata K, Kenshalo DR Jr, Dubner R. Effects of central administration of opioids on facial scratching in monkeys. Brain Res 1992;585:315-7.
57. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993;53:1253-7.
58. Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979;115:1366-7.
59. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-9.
60. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995;123:161-7.
61. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998;27:679-84.
62. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999;41:431-4.
63. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997;113:1264-9.
64. Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22.
65. Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000;118:431-2.
66. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. Q J Med 2002;95:547-52.
67. McRae CA, Prince MI, Hudson M, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125:591-6.
68. Mitchell JE. Naltrexone and hepatotoxicity. Lancet 1986;1:1215.
69. Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996;91:1022-3.
70. Sax DS, Kornetsky C, Kim A. Lack of hepatotoxicity with naltrexone treatment. J Clin Pharmacol 1994;34:898-901.
71. Bomzon A, Jacob G, Better OS. Jaundice and the kidney. In: Epstein M, editor. The kidney in liver disease, 4th ed. Philadelphia: Hanley & Belfus; 1996. pp 423-46.
72. Jacob G, Said O, Finberg J, Bomzon A. Peripheral vascular neuroeffector mechanisms in experimental cholestasis. Am J Physiol 1993;265:G579-G86.
73. Pak JM, Lee SS. Vasoactive effects of bile salts in cirrhotic rats: in vivo and in vitro studies. Hepatology 1993;18:1175-81.
74. Inan M, Sayek I, Tel BC, Sahin-Erdemli I. Role of endotoxin and nitric oxide in the pathogenesis of renal failure in obstructive jaundice. Br J Surg 1997;84:943-7.
75. Cioffi WG, DeMeules JE, Kahng KU, Wait RB. Renal vascular reactivity in jaundice. Surgery 1986;100:356-62.
76. Song E, Segal I, Hodkinson J, Kew MC. Sinus bradycardia in obstructive jaundice: correlation with total serum bile acid concentrations. S Afr Med J 1983;64:548-51.
77. Binah O, Bomzon A, Blendis LM, Mordohovich D, Better OS. Obstructive jaundice blunts myocardial contractile response to isoprenaline in the dog: a clue to the susceptibility of jaundiced patients to shock? Clin Sci (London) 1985;69:647-53.
78. Nahavandi A, Dehpour AR, Mani AR, Homayounfar H, Abdoli A, Abdolhoseini MR. The role of nitric oxide in bradycardia of rats with obstructive cholestasis. Eur J Pharmacol 2001;411:135-41.
79. Mani AR, Nahavandi A, Moosavi M, Safarinejad R, Dehpour AR. Dual nitric oxide mechanisms of cholestasis-induced bradycardia in the rat. Clin Exp Pharmacol Physiol 2002;29:905-8.
80. Cadet P, Bilfinger TV, Fimiani C, Peter D, Stefano GB. Human vascular and cardiac endothelia express mu opiate receptor transcripts. Endothelium 2000;7:185-91.
81. Sadeghipour H, Dehghani M, Dehpour AR. Role of opioid and nitric oxide systems in the nonadrenergic noncholinergic-mediated relaxation of corpus cavernosum in bile duct-ligated rats. Eur J Pharmacol 2003;460:201-7.
82. Moller S, Henriksen JH. Pathogenesis and pathophysiology of hepatorenal syndrome: is there scope for prevention? Aliment Pharmacol Ther 2004;20:42-3.
83. Treiber G, Csepregi A, Malfertheiner P. The pathophysiology of portal hypertension. Dig Dis 2005;23:6-10.
84. Thornton JR, Dean H, Losowsky MS. Is ascites caused by impaired hepatic inactivation of blood borne endogenous opioid peptides? Gut 1988;29:1167-72.
85. Horvath G. Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous mu-opioid receptor agonists. Pharmacol Ther 2000;88:437-63.
86. Leehey DJ, Gollapudi P, Deakin A, Reid RW. Naloxone increases water and electrolyte excretion after water loading in patients with cirrhosis and ascites. J Lab Clin Med 1991;118:484-91.
87. Lee SS, Hadengue A, Moreau R, Girod C, Jiron MI, Lebrec D. Naloxone does not alter haemodynamics in cirrhosis. Studies in humans and rats. J Hepatol 1987;5:149-53.
88. Bosch-Marce M, Jimenez W, Angeli P, Leivas A, Claria J, Graziotto A, et al. Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 1995;109:217-23.
89. Gines P, Jimenez W. Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. J Hepatol 1996;24:506-12.
90. Moreau R, Cailmail S, Hamon G, Lebrec D. Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis. J Gastroenterol Hepatol 1996;11:857-63.
91. Bosch-Marce M, Poo JL, Jimenez W, Bordas N, Leivas A, Morales-Ruiz M, et al. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J Pharmacol Exp Ther 1999;289:194-201.
92. Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, et al. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 2000;32:38-42.
93. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004;5:2-19.
94. Jones EA, Skolnick P, Gammal SH, Basile AS, Mullen KD. The gamma-aminobutyric acid A (GABAA) receptor complex and hepatic encephalopathy. Some recent advances. Ann Intern Med 1989;110:532-46.
95. Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997;25:1303-5.
96. Butterworth RF. Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems. Curr Opin Neurol 2000;13:721-7.
97. Sasaki K, Fan LW, Tien LT, Ma T, Loh HH, Ho IK. The interaction of morphine and gamma-aminobutyric acid (GABA)ergic systems in anxiolytic behavior: using mu-opioid receptor knockout mice. Brain Res Bull 2002;57:689-94.
98. Bergasa NV, Rothman RB, Mukerjee E, Vergalla J, Jones EA. Up-regulation of central mu-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for increased sensitivity to morphine in liver failure. Life Sci 2002;70:1701-8.
99. Laidlaw J, Read AE, Sherlock S. Morphine tolerance in hepatic cirrhosis Gastroenterology 1961;40:389-96.
100. Yurdaydin C. The central opioid system in liver disease and its complications. Metab Brain Dis 2001;16:79-83.
101. de Waele JP, Audet RM, Leong DK, Butterworth RF. Portacaval anastomosis induces region-selective alterations of the endogenous opioid system in the rat brain. Hepatology 1996;24:895-901.
102. Yurdaydin C, Karavelioglu D, Onaran O, Celik T, Yasa MH, Uzunalimoglu O. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol 1998;29:796-801.
103. Ozsoylu S, Kocak N. Naloxone in hepatic encephalopathy. Am J Dis Child 1985;139:749-50.
104. Yurdaydin C, Li Y, Ha JH, Jones EA, Rothman R, Basile AS. Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists. J Pharmacol Exp Ther 1995;273:185-92.
105. Homayoun H, Sayyah M, Dehpour AR. The additive effect of opioids and nitric oxide in increasing pentylenetetrazole-induced seizure threshold in cholestatic mice. J Gastroenterol Hepatol 2002;17:96-101.
106. Swain MG, Vergalla J, Bergasa NV, Jones EA. Sympathetic nerves, but not the adrenal gland, contribute to elevated plasma levels of met-enkephalin in rats with acute cholestatic hepatitis. Regul Pept 1993;46:535-42.
107. Swain MG, MacArthur L, Vergalla J, Jones EA. Adrenal secretion of BAM-22P, a potent opioid peptide, is enhanced in rats with acute cholestasis. Am J Physiol 1994;266:G201-5.
108. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-33.
109. D'Amato R, Holaday JW. Multiple opioid receptors in endotoxic shock: evidence for delta involvement and mu-delta interactions in vivo. Proc Natl Acad Sci USA 1984;81:2898-901.
110. Napolitano L, Chernow B. Endorphins in circulatory shock. Crit Care Med 1988;16:566-7.
111. Goumon Y, Bouret S, Casares F, Zhu W, Beauvillain JC, Stefano GB. Lipopolysaccharide increases endogenous morphine levels in rat brain. Neurosci Lett 2000;293:135-8.
112. Le Moine O, Soupison T, Sogni P, Marchant A, Moreau R, Hadengue A, et al. Plasma endotoxin and tumor necrosis factor-alpha in the hyperkinetic state of cirrhosis. J Hepatol 1995;23:391-5.
113. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000;118:937-44.
114. Bigatello LM, Broitman SA, Fattori L, Di Paoli M, Pontello M, Bevilacqua G, et al. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am J Gastroenterol 1987;82:11-5.